Pacira BioSciences' Capital Expenditures fell 5.43% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year increase of 67.05%. This contributed to the annual value of $10.6 million for FY2024, which is 29.85% down from last year.
According to the latest figures from Q3 2025, Pacira BioSciences' Capital Expenditures is $3.9 million, which was up 43.49% from $2.7 million recorded in Q2 2025.
Pacira BioSciences' Capital Expenditures' 5-year high stood at $13.1 million during Q3 2021, with a 5-year trough of $1.6 million in Q2 2024.
Over the past 3 years, Pacira BioSciences' median Capital Expenditures value was $3.4 million (recorded in 2023), while the average stood at $3.7 million.
In the last 5 years, Pacira BioSciences' Capital Expenditures plummeted by 70.99% in 2023 and then surged by 201.41% in 2025.
Over the past 5 years, Pacira BioSciences' Capital Expenditures (Quarterly) stood at $9.2 million in 2021, then crashed by 40.08% to $5.5 million in 2022, then slumped by 67.26% to $1.8 million in 2023, then climbed by 17.80% to $2.1 million in 2024, then fell by 5.43% to $3.9 million in 2025.
Its last three reported values are $3.9 million in Q3 2025, $2.7 million for Q2 2025, and $8.5 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value